术前抗凝或抗血小板治疗对急性A型主动脉夹层手术结局的影响
基于STS成人心脏手术数据库2017至2022年20,530例首次胸骨正中切开修复急性A型主动脉夹层的回顾性队列研究,采用倾向性评分匹配比较术前服用DOAC、华法林或DAPT患者与对照组的结局。结果显示三组患者手术死亡率及出血再手术率均高于匹配对照组,DOAC或DAPT患者是否延迟手术对结局的影响尚需进一步研究。
要点
- 术前服用DOAC、华法林或DAPT的ATAAD患者手术死亡率和出血再手术风险显著增加。
- DOAC和DAPT患者出血再手术风险分别是对照组的1.8倍和2.2倍。
- DOAC患者延迟至入院次日手术死亡率有降低趋势但未达统计学显著。
核心结论
- 术前服用DOAC、DAPT或华法林的ATAAD患者首次手术死亡率及出血并发症增加。
研究设计与样本
- 回顾性队列研究,纳入STS成人心脏手术数据库2017至2022年20,530例首次胸骨正中切开修复ATAAD患者。
- 采用倾向性评分匹配,为每例DOAC(n=625)、华法林(n=245)和DAPT(n=525)患者匹配2例对照。
主要发现
- 匹配对照比较,DOAC组死亡率24.8% vs 17.9%(OR 1.50 [1.2,2.0],p<0.001)。
- 华法林组死亡率26.7% vs 19.2%(OR 1.6 [1.1,2.4],p=0.02)。
- DAPT组死亡率27.4% vs 20.1%(OR 1.5 [1.2,2.0],p=0.001)。
- DOAC组出血再手术率12.0% vs 7.0%(OR 1.8 [1.3,2.5],p=0.001);DAPT组15.2% vs 7.3%(OR 2.2 [1.6,3.2],p<0.001)。
- 华法林组出血再手术率11.4% vs 7.8%(OR 1.5 [0.9,2.6],p=0.11)。
关键数值与推荐
- 76.5%(478/625)的DOAC患者和71.2%(374/525)的DAPT患者在入院当日接受手术。
- DOAC患者入院第1天及以后手术死亡率17.4% vs 25.0%(p=0.08),DAPT患者无差异。
临床怎么用
- 对术前服用DOAC、华法林或DAPT的ATAAD患者,应充分评估出血风险并做好围术期血液制品准备。
- DOAC或DAPT患者是否延迟手术以降低死亡率需进一步研究,目前不应常规延迟。
局限性
- 回顾性研究设计存在选择偏倚可能。
- 原文未报告延迟手术与死亡率关系的多因素校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients taking direct oral anticoagulants (DOACs), warfarin, or dual antiplatelet therapy (DAPT) who present with acute Type A aortic dissection (ATAAD) are a unique challenge. Our objective was to investigate the surgical outcomes of this patient population. METHODS: A retrospective cohort study was performed of 20,530 patients who underwent first-time sternotomy repair of ATAAD in the Society of Thoracic Surgeons Adult Cardiac Surgery Database from 2017 to 2022. Propensity score matching was used to pair each DOAC (n=625), warfarin (n=245), and DAPT (n=525) patient with 2 controls. Outcomes included operative mortality and reoperation for bleeding. RESULTS: Compared to matched controls, mortality was higher for patients on DOACs (24.8% vs 17.9%, OR 1.50 [1.2,2.0], p<0.001), warfarin (26.7% vs 19.2%, OR 1.6 [1.1,2.4], p=0.02), or DAPT (27.4% vs 20.1%, OR 1.5 [1.2,2.0], p=0.001). Reoperation for bleeding was higher for DOACs (12.0% vs 7.0%, OR 1.8 [1.3,2.5], p=0.001) and DAPT (15.2% vs 7.3%, OR 2.2 [1.6,3.2], p<0.001), and trended that way for warfarin (11.4% vs 7.8%, OR 1.5 [0.9,2.6], p=0.11). Most DOAC (76.5% [478/625]) and DAPT (71.2% [374/525]) patients underwent surgery on the day of admission. While there was a non-significant difference toward lower mortality for DOAC patients who had surgery on day ≥1 (17.4% vs 25.0%, p=0.08), there was no difference for those on DAPT. CONCLUSIONS: Patients undergoing first-time surgery for ATAAD on DOACs, DAPT, or warfarin preoperatively had increased mortality and bleeding complications. For those on DOACs or DAPT, further study is required to investigate whether delaying surgery impacts outcomes.
引用
- Kelly JJ, Chen Z, Thalji N, et al. Surgery for Acute Type A Aortic Dissection on Preoperative Anticoagulants and Antiplatelet Agents. Ann Thorac Surg. 2026. PMID: 42822618. doi:10.1016/j.athoracsur.2026.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。